Stock AZTR AZITRA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Azitra, Inc.

Equities

AZTR

US05479L1044

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 16:37:31 20/05/2024 BST 		5-day change 1st Jan Change
0.186 USD +2.20% Intraday chart for Azitra, Inc. -3.62% -80.30%
05-10 Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting CI
05-09 Azitra, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2023 2024 2025 2026
Capitalization 1 11.13 5.242 - -
Enterprise Value (EV) 1 11.13 5.242 5.242 5.242
P/E ratio -0.5 x -0.44 x -0.47 x -0.44 x
Yield - - - -
Capitalization / Revenue 16.2 x - 3.49 x -
EV / Revenue 16.2 x - 3.49 x -
EV / EBITDA - - - -
EV / FCF -1.51 x -0.56 x -0.51 x -0.4 x
FCF Yield -66.4% -179% -197% -251%
Price to Book - - - -
Nbr of stocks (in thousands) 12,098 28,805 - -
Reference price 2 0.9200 0.1820 0.1820 0.1820
Announcement Date 15/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 - 0.686 - 1.5 -
EBITDA - - - - -
EBIT 1 - -7.616 -8.693 -13.33 -11.93
Operating Margin - -1,110.26% - -888.77% -
Earnings before Tax (EBT) - - - - -
Net income 1 -10.68 -12.64 -8.693 -9.563 -11.93
Net margin - -1,842.44% - -637.53% -
EPS 2 -90.47 -1.830 -0.4100 -0.3900 -0.4100
Free Cash Flow 1 - -7.389 -9.371 -10.31 -13.14
FCF margin - -1,077.1% - -687.27% -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 21/02/23 15/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q3 2023 Q4 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - 0.09 - - -
EBITDA - - - - -
EBIT 1 - -2.58 -1.892 -1.911 -1.929
Operating Margin - -2,866.71% - - -
Earnings before Tax (EBT) - - - - -
Net income 1 -1.943 -2.454 -1.892 -1.911 -1.929
Net margin - -2,726.43% - - -
EPS 2 -0.1600 - -0.0900 -0.0800 -0.0800
Dividend per Share - - - - -
Announcement Date 14/11/23 15/03/24 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 1 - -7.39 -9.37 -10.3 -13.1
ROE (net income / shareholders' equity) - - - - -
ROA (Net income/ Total Assets) - - - - -
Assets 1 - - - - -
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex - 0.03 - - -
Capex / Sales - 3.87% - - -
Announcement Date 21/02/23 15/03/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.182 USD
Average target price
3.5 USD
Spread / Average Target
+1,823.08%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
AZITRA, INC. Stock Azitra, Inc.
-80.30% 5.24M
MODERNA, INC. Stock Moderna, Inc.
+38.84% 50.93B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.14% 42.12B
LONZA GROUP AG Stock Lonza Group AG
+49.62% 42.05B
CELLTRION, INC. Stock Celltrion, Inc.
-7.20% 29.18B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.78% 26.02B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.44% 18.9B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+8.00% 13.21B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.56% 12.17B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.91% 12.16B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. AZTR Stock
  4. Financials Azitra, Inc.